BCL2L1 and small cell lung carcinoma: As we move forward, a multidisciplinary approach encompassing preclinical investigations, translational research, and clinical trials will be instrumental in realizing the full potential of dual BCL-xL/2 degradation in improving outcomes for SCLC patients.